Active, Not Recruiting
A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of VIS171 in Participants With Autoimmune Disease(s)
NCT06799520
- Conditions
- Alopecia, Alopecia Areata, Alopecia Areata (AA), +10 more
- Locations
-
- Visterra Investigational Site Sofia, Bulgaria
- Visterra Investigational Site Chisinau, Moldova
- Visterra Investigational Site Bucharest, Romania
- Visterra Investigational Site Cluj-Napoca, Romania